Tags : Treat


MTPA and Aquestive Sign a License and Supply Agreement for

Shots: Aquestive will receive upfront, milestones, royalties on net sales for Exservan (oral film formulation) in the US and will earn revenue pursuant to the exclusive supply agreement MTPA to commercialize Exservan in the US while Aquestive will serve as the exclusive sole manufacturer and supplier for the product Exservan is an oral film formulation […]Read More


Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for

Shots: MiNA to receive $267.6M in up front, exclusivity fee on first neurological target and will be eligible to receive research, development, regulatory and commercial milestones along with royalties Servier will lead pre/ clinical development of lead candidates and will have the rights to commercialize any products that emerges from the collaboration The collaboration integrates […]Read More


Richter Acquires Janssen’s Evra Transdermal Contraceptive Patch Assets for $263.5M

Shots: Richter signed an asset purchase agreement with Janssen for Evra transdermal contraceptive patch assets outside the US. The total deal value is $263.5M The companies also signed a transitional business license agreement and a series of other related agreements to run the business without interruption during the period required to transfer the marketing authorizations […]Read More


Shionogi Receives MHLW’s Approval for Xofluza’s sNDA to Treat Post-Exposure

Shots: The approval is based on P-III BLOCKSTONE study assessing Xofluza (baloxavir marboxil, 10/20mg) vs PBO in patients in household members aged ≥12yrs. who was living with someone with an influenza infection confirmed by a rapid influenza diagnostic test Result: The proportion of household members who developed influenza (1.9% vs 13.6%); well tolerated with no […]Read More